Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (6472)	1/15/2001 11:06:12 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

Joe, very interesting. Especially Dr Gould's background. EOM

To: Joe Krupa who wrote (6472)	1/27/2001 11:18:38 PM
From: Cal Gary	Respond to of 14101

Hi Joe, guess what? Provalis is no stranger to diclofenac according to page 12 in its 2000 Annual Report. This performance was influenced by the reduced sales of diclofenac to Parke Davis in the second half of 2000 which was due to perturbed ordering patterns connected with the move of its packaging site. Sales of diclofenac have now recovered strongly in the first quarter of the current financial year. The sales of promoted products by the Provalis sales force increased by 16%, moving this business into net profit for the first time in the Company’s history making a contribution of £0.5m (1999: loss of £0.1m). Does this translate into quicker sales by Provalis' sales force?? Mark, Wolf, or anyone, what exactly is Provalis' role with Diclofenac? Distributor? And a guess, for migraine (AR page 2. But isn't Diclofenac used for OA?) And why Parke-Davis? Parke-Davis, a division of Warner-Lambert Company, is devoted to discovering, developing, manufacturing, and marketing quality pharmaceutical products. Its central research focus is on heart disease, diabetes, anti-infectives, central nervous system, and women's healthcare. Warner-Lambert Company is a worldwide company employing approximately 38,000 people, and along with Parke-Davis, is headquartered in Morris Plains, New Jersey. Warner-Lambert achieved sales of more than $7 billion in 1996, and will invest more than $600 million worldwide in research and development in 1997. Park-Davis is an old American pharm, now related to Warner-Lamber and Pfizer. Re: CV for Dr. Phil Gould, and his association with drug delivery systems. Provalis is no longer focusing on drug delivery technologies and the Board is seeking to sell most of the intellectual property held in the area. Option and other agreements have now been signed with a number of biotechnology and pharmaceutical companies that could lead to those companies acquiring the intellectual property in due course. However, Provalis intends to retain its intellectual property on the dispersion-based drug delivery technology associated with the development of the product Macrulin™ - its oral anti-diabetic therapy using insulin. Discussions are being conducted with a number of companies to determine if there is a way for them to fund the formal Phase II clinical trials for this product. They divest some drug delivery IP and technologies a year ago, then in comes our carrier the next.